0001193125-26-056029
SEC filingNewAmsterdam Pharma Company N.V. reported a fiscal year 2025 net loss of $203.8 million, driven by significant operating expenses of $248.2 million that far exceeded its $22.5 million in revenue. The company generated substantial interest income of $27.6 million and recorded fair value gains on warrants of $22.8 million, partially offsetting operating losses. Cash flow from operations was negative $147.8 million, while investing activities consumed $174.9 million primarily for marketable securities purchases. The company maintains a strong liquidity position with $490.0 million in cash and cash equivalents and total current assets of $675.7 million, supported by $683.4 million in shareholders' equity. Research and development expenses totaled $141.8 million, reflecting continued investment in pharmaceutical development programs.
NewAmsterdam Pharma Company N.V. reported a challenging fiscal year 2025 with a net loss of $203.8 million, driven by operating losses of $225.7 million. Revenue of $22.5 million was substantially outweighed by total operating expenses of $248.2 million, consisting of $141.8 million in research and development expenses and $106.4 million in selling, general and administrative expenses. The company's loss before tax was $203.8 million, with a minimal income tax benefit of $1,000. Total comprehensive loss for the year was $203.5 million, slightly improved from the net loss due to a $326,000 unrealized gain on available-for-sale securities. Basic and diluted net loss per ordinary share was $2.00.
The company reported $22.5 million in revenue for fiscal year 2025. No segment breakdown, geographic mix, or specific revenue drivers are disclosed in the provided financial data. The revenue figure represents the total recognized during the period without further categorization or comparative analysis against prior periods. The absence of segment data suggests the company operates as a single reporting unit or has not disclosed segment-level information in the provided financial statements.
The company operated at a significant loss with operating expenses of $248.2 million exceeding revenue by $225.7 million, resulting in negative operating margins. Research and development expenses of $141.8 million represented the largest cost component, followed by selling, general and administrative expenses of $106.4 million. Non-operating items provided some offset, including $27.6 million in interest income, $22.8 million in fair value gains on warrants, and $13.1 million in foreign exchange gains. The company's cost structure reflects its development-stage status with substantial investment in pharmaceutical research programs.
Operating activities consumed $147.8 million in cash, primarily from the $203.8 million net loss partially offset by $59.4 million in share-based compensation and $18.8 million in fair value changes. Investing activities used $174.9 million, with $296.7 million in marketable securities purchases partially offset by $122.1 million in maturities. Financing activities provided $29.5 million, mainly from $29.5 million in option exercise proceeds. The balance sheet shows strong liquidity with $490.0 million in cash and cash equivalents, $146.2 million in current marketable securities, and total current assets of $675.7 million. Total liabilities are $85.9 million, with shareholders' equity of $683.4 million.
No forward-looking guidance, management commentary, strategic priorities, or specific risk factors are provided in the financial data. The filing contains only financial statement information without accompanying management discussion and analysis, outlook statements, or future projections. The company's financial position suggests continued investment in research and development activities, but specific guidance on future performance, clinical trial milestones, or regulatory developments is not included in the provided data.